LITTLE ROCK, Ark., March 26, 2004 (PRIMEZONE) — Cytomedix, Inc. (CYME:OTC.OB) today announced it has received a favorable ruling from United States […]
As the Voluven molecule is smaller than those of other available hydroxyethyl starch products, it is associated with less plasma accumulation and can be safely used in patients with renal impairment.